



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**17.03.2021 Bulletin 2021/11**

(45) Date of publication and mention  
of the grant of the patent:  
**06.01.2021 Bulletin 2021/01**

(21) Application number: **16706528.3**

(22) Date of filing: **22.02.2016**

(51) Int Cl.:  
**A61K 41/00** <sup>(2020.01)</sup> **A61N 5/10** <sup>(2006.01)</sup>  
**A61K 38/16** <sup>(2006.01)</sup> **A61K 47/64** <sup>(2017.01)</sup>

(86) International application number:  
**PCT/EP2016/000303**

(87) International publication number:  
**WO 2016/134838 (01.09.2016 Gazette 2016/35)**

(54) **COMBINED VACCINATION/RADIOTHERAPY FOR CANCER TREATMENT**  
KOMBINIERTE IMPFUNGS-/STRAHLENTHERAPIE ZUR KREBSBEHANDLUNG  
VACCINATION/RADIOTHÉRAPIE COMBINÉES POUR LE TRAITEMENT DU CANCER

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **23.02.2015 PCT/EP2015/000507**

(43) Date of publication of application:  
**03.01.2018 Bulletin 2018/01**

(73) Proprietors:  
• **Institut Curie**  
**75005 Paris (FR)**  
• **Centre National de la Recherche Scientifique**  
**(C.N.R.S.)**  
**75794 Paris Cedex 16 (FR)**  
• **Institut Gustave Roussy**  
**94805 Villejuif Cédex (FR)**  
• **Assistance Publique-Hôpitaux de Paris (APHP)**  
**75004 Paris (FR)**  
• **Institut National de la Santé et de la Recherche**  
**Médicale**  
**75654 Paris 13 (FR)**  
• **Université de Paris**  
**75006 Paris (FR)**

(72) Inventors:  
• **DEUTSCH, Eric**  
**75004 Paris (FR)**  
• **LUDGER, Johannes**  
**92400 Courbevoie (FR)**  
• **MONDINI, Michèle**  
**75013 Paris (FR)**  
• **NIZARD, Mevyn**  
**94260 Fresnes (FR)**  
• **PERFETTINI, Jean-Luc**  
**77100 Meaux (FR)**  
• **TARTOUR, Eric**  
**75003 Paris (FR)**  
• **TRAN, Thi**  
**75018 Paris (FR)**

(74) Representative: **Barbot, Willy**  
**Simodoro-ip**  
**82, rue Sylvabelle**  
**13006 Marseille (FR)**

(56) References cited:  
**EP-A1- 2 740 491 WO-A2-2012/177624**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- HAICHEURN ET AL: "The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 165, no. 6, 15 September 2000 (2000-09-15), pages 3301-3308, XP002228666, ISSN: 0022-1767 cited in the application
- REBECCA G. POMERANTZ ET AL: "The role of epidermal growth factor receptor in head and neck squamous cell carcinoma", CURRENT ONCOLOGY REPORTS, vol. 5, no. 2, 1 April 2003 (2003-04-01), pages 140-146, XP055205530, ISSN: 1523-3790, DOI: 10.1007/s11912-003-0101-z
- R. HASSAN: "Tumor-Directed Radiation and the Immunotoxin SS1P in the Treatment of Mesothelin-Expressing Tumor Xenografts", CLINICAL CANCER RESEARCH, vol. 12, no. 16, 15 August 2006 (2006-08-15), pages 4983-4988, XP055157621, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-06-0441